Astellas vs. Zydus: Consent Judgment Blocks Generic Myrbetriq® Entry
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Astellas Pharma, Inc. v. Zydus Lifesciences Limited et al. |
| Case Number | 1:24-cv-00940 (D. Del.) |
| Court | District of Delaware |
| Duration | Aug 2024 – Feb 2026 555 days |
| Outcome | Plaintiff Win — Consent Judgment |
| Patents at Issue | |
| Accused Products | Mirabegron Extended-Release Tablets (25mg & 50mg) |
Case Overview
The Parties
⚖️ Plaintiff
Leading Japanese multinational pharmaceutical company, manufacturer of Myrbetriq® (mirabegron) for overactive bladder.
🛡️ Defendant
Major Indian generic pharmaceutical manufacturer with broad ANDA filings across therapeutic categories.
Patents at Issue
This landmark case involved four U.S. patents protecting mirabegron extended-release oral tablet formulations. These patents cover composition, dosing regimens, and related pharmaceutical claims, demonstrating Astellas’s strategy of continuing prosecution to obtain later-expiring patent protection.
- • U.S. Patent No. 10,842,780 — Mirabegron extended-release formulation
- • U.S. Patent No. 11,707,451 — Mirabegron composition and method of use
- • U.S. Patent No. 12,059,409 — Later-expiring mirabegron formulation patent
- • U.S. Patent No. 12,097,189 — Further mirabegron extended-release patent
Developing a new pharmaceutical formulation?
Check if your drug formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The parties entered a consent judgment on February 19, 2026, resolving all four related civil actions simultaneously. Zydus stipulated that the ‘780, ‘451, ‘409, and ‘189 patents are valid and enforceable, and that at least one claim of each patent is infringed by its ANDA products. Zydus is enjoined from making, using, selling, offering to sell, importing, or distributing the generic mirabegron products in the United States until expiration of all four patents.
Key Legal Issues
This case was initiated as a patent infringement action under the Hatch-Waxman Act, triggered by Zydus’s Paragraph IV certification in ANDA No. 209488. The consent judgment’s admission of validity and infringement, rather than a negotiated entry date, suggests Astellas held significant litigation leverage, likely bolstered by the strength of its later-issued patents (‘409 and ‘189).
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related ANDA filings and their status
- See which companies are most active in generic challenges
- Understand formulation claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your API or formulation details
- AI identifies potentially blocking formulation patents
- Get actionable risk assessment report
High Risk Area
Mirabegron extended-release formulations
4 Patents at Issue
In mirabegron formulation space
Formulation-Around Options
Available for some claims
✅ Key Takeaways
Consent judgments extracting validity and infringement admissions create stronger portfolio-wide deterrence than date-certain settlement agreements.
Search related case law →Multi-case consolidation of related ANDA disputes is an effective mechanism to force portfolio-wide resolution.
Explore precedents →Frequently Asked Questions
Four U.S. patents covering mirabegron extended-release formulations: U.S. Patent Nos. 10,842,780; 11,707,451; 12,059,409; and 12,097,189.
Zydus stipulated to validity, enforceability, and infringement of all four patents in connection with its ANDA No. 209488 for generic mirabegron tablets, agreeing to a market exclusion injunction through patent expiration.
The validity and infringement admissions, while ANDA-specific, strengthen Astellas’s litigation posture against other Paragraph IV challengers and may deter competing ANDA certifications against the same patent estate.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Center – Search Patent Nos. 10842780, 11707451, 12059409, 12097189
- PACER – D. Del. Case 1:24-cv-00940
- FDA ANDA Database – ANDA No. 209488
- PatSnap – IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.